Home » Topics » Infection, BioWorld Science

Infection, BioWorld Science
RSS

Therapeutics Solutions plans to use StemVacs to treat COVID-19

March 18, 2021

FDA clears initiation of phase I study of Meissa's COVID-19 vaccine candidate MV-014-212

March 18, 2021

Corat gains clearances to begin phase Ib/II trial of COR-101 for COVID-19

March 17, 2021

UCB describes new antimalarial compounds

March 17, 2021

FDA clears IND for phase II study of CYTO-205 as treatment of mild COVID-19

March 17, 2021

Arbutus receives regulatory approval for phase Ia/Ib trial of AB-836 in chronic HBV infection

March 17, 2021

First patient dosed in phase I study of emricasan in mild symptomatic COVID-19

March 17, 2021

Moderna initiates phase I study of its next-generation COVID-19 vaccine, mRNA-1283

March 17, 2021

Moderna begins phase II/III pediatric trial of COVID-19 vaccine candidate mRNA-1273

March 16, 2021

Phase III evaluation starts of Medicago's COVID-19 vaccine candidate with GSK adjuvant

March 16, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.